Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral, Raises Price Target to $119

Benzinga Newsdesk www.benzinga.com Negative 70.3%

Neg 70.3% Neu 0% Pos 0%

Cantor Fitzgerald analyst Kristen Kluska downgrades Monopar Therapeutics (NASDAQ:MNPR) from Overweight to Neutral and raises the price target from $109 to $119.